Teva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at the 2023 American Academy of Neurology Annual Meeting
Dose proportionality and bioequivalence studies demonstrate once-daily AUSTEDO XR is therapeutically equivalent to twice-daily AUSTEDO® tablets The U.S. Food and Drug Administration ... | April 11, 2023
United States Eric Hughes Teva Pharmaceuticals Teva Pharmaceutical Industries Ltd Drug Administration American Academy Of Neurology
Source: marketscreener.com